EGFR and non-small cell lung carcinoma: After promising results in preclinical models [86], an afatinib and cetuximab combination achieved a partial response (2.7 to 17.6 months) in 3/4 NSCLC patients with EGFR Ex20ins previously treated with platinum-based chemotherapy [87].